Exscientia's AI-driven systems learn from vast repositories of discovery data and experienced drug hunters to design millions of novel compounds, pre-assessing each for predicted potency, selectivity, ADME, and other key criteria. The best compounds are selected for synthesis and assay, generating new experimental data that is integrated into the next design cycle. Exscientia has already delivered exceptional productivity, generating candidates in roughly one-quarter of the time of traditional approaches. Its patient-first AI process is comprised of Precision Target, Precision Design, Precision Experiment, and Precision Medicine, and it generates revenue from service fees and licensing fees related to drug discovery agreements.